Relief Therapeutics Grants Exclusive U.S. Rights to Eton Pharmaceuticals for PKU GOLIKE
Friday, 22 March 2024, 07:31
Exclusive U.S. License Agreement
Relief Therapeutics has granted Eton Pharmaceuticals the exclusive rights to commercialize GOLIKE products in the US.
Strategic Partnership
- Significant opportunity for expansion in the PKU treatment sector.
- Milestones and royalties included in the agreement.
The collaboration between Relief Therapeutics and Eton Pharmaceuticals signifies a strong alliance within the pharmaceutical industry.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.